NCT07472621 2026-03-16
Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma
Henan Cancer Hospital
Not yet recruiting
Clinical Trials
8 trialsNCT07443137 2026-03-02
CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study)
Stanford University
Phase 1 Not yet recruiting
NCT07389356 2026-02-05
Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCL
The First Affiliated Hospital with Nanjing Medical University
Phase NA Not yet recruiting
NCT07326371 2026-01-08
Glofitamab Combined With CAR-T Therapy in R/R DLBCL
Ruijin Hospital
Phase 2 Not yet recruiting
NCT06985576 2025-12-18
Long-term Study to Evaluate Safety and Persistence of GF-CART01
GenomeFrontier Therapeutics TW Co., Ltd.
Not yet recruiting
NCT07231250 2025-11-19
Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT07066436 2025-07-15
ImmunoMRI for Assessment of Tumor-associated Macrophages
Medical University of Vienna
Phase EARLY_PHASE1 Not yet recruiting
NCT07034508 2025-06-24
A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Not yet recruiting